Stock Movers Sanofi Drops, Jet2 Warning, Burberry Rise
Sep 4, 2025
Sanofi's latest drug trial results have disappointed investors, raising questions about its future prospects. Jet2 shares plummeted by 25%, amidst a significant surge in trading volume, reversing previous gains. In a bright spot, Burberry is set to make a triumphant return to the FTSE 100 Index after a year away, thanks to a new strategy that highlights its iconic heritage. This juxtaposition of struggles and comebacks exemplifies the volatility in the stock market.
AI Snips
Chapters
Transcript
Episode notes
Sanofi Drug Fell Short Versus Dupixent
- Sanofi's new eczema drug improved skin but underperformed versus its existing blockbuster Dupixent.
- Investors viewed the relative shortfall as a meaningful setback, pushing shares sharply lower.
Pipeline Uncertainty Hurts Investor Confidence
- Sanofi now faces uncertainty across multiple late-stage programs after mixed pulmonary trial results.
- The company needs clearer wins to reassure investors amid recent pipeline disappointments.
Jet2 Profit Warning From Last‑Minute Bookings
- Jet2 warned profits will be at the lower end of consensus and cited limited visibility from last‑minute bookings.
- Unsold winter seats and a plan to reduce capacity drove a large share drop and analyst cuts.